Serum concentrations of galectin-3 in patients with cardiac syndrome X

Bozçalı, Evin; Polat, Veli; Açıksarı, Gönül; Opan, Selçuk; Bayrak, İbrahim; Paker, Nurcan; Karakaya, Osman

doi:10.1016/j.atherosclerosis.2014.09.014

Cited by 19 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inter-study differences may conceivably be ascribed to smaller population size, different examination modalities and random variation. Few other studies have investigated biomarkers in small CMD populations: One study found increased activation of circulating progenitor cells related to CMD in 123 women [46], while a study by Bozcali et al in 115 cardiac syndrome X patients found higher levels of the inflammation and fibrosis biomarker galectin-3 (Gal3) compared with healthy controls [47]. In the present study, there was no significant relation between Gal3 and CFVR.…”

Section: Discussioncontrasting

confidence: 53%

Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction

Schrøder

Mygind

Frestad

et al. 2019

IJC Heart & Vasculature

View full text Add to dashboard Cite

Background Studies that evaluate larger numbers of protein biomarkers in patients with coronary microvascular dysfunction (CMD) have not previously been performed, and very little is known concerning the pathogenetic mechanisms leading to CMD. Our objective was to analyze associations between a broad cardiovascular disease (CVD) protein biomarker assay and CMD, and further explore internal biomarker relations in order to identify possible targets for future treatment interventions. Methods In 174 women with angina pectoris and no significant obstructive coronary artery disease (<50% stenosis on invasive coronary angiography), CMD was assessed by transthoracic Doppler echocardiography measuring coronary flow velocity reserve (CFVR). Blood samples were analyzed with a CVD proteomic panel encompassing 92 biomarkers. The relation between biomarkers and CFVR was evaluated by regression analysis, and possible interrelations between significant biomarkers were investigated by principal component analysis (PCA). Results Median age (SD) was 64 years (9.8), median CFVR (IQR) was 2.3 (1.9–2.7), and 28% of patients had CFVR < 2.0. Eighteen biomarkers were significantly correlated with CFVR. In PCA, 8 of the biomarkers significantly related to CFVR showed high loadings on principal component 1 (PC1). The component scores of PC1 were significantly related to CFVR ( p = 0.002). The majority of the 8 interrelated PC1 biomarkers were related to the pro-inflammatory TNF-α – IL-6 – CRP pathway. Conclusion Eighteen protein biomarkers were significantly associated with CMD. Eight biomarkers were interrelated in PCA, and share connection with pro-inflammatory pathways, highlighting a possible important role of inflammation in CMD.

show abstract

Section: Discussioncontrasting

confidence: 53%

Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction

Schrøder

Mygind

Frestad

et al. 2019

IJC Heart & Vasculature

View full text Add to dashboard Cite

show abstract

“…Prior studies have also reported a positive association between galectin-3 and hsCRP, although the strength of association has generally been weaker than seen in our study (r%0.13 to 0.25). 24,25,35 Further investigation is warranted regarding why these patients develop an inflammatory response, the typical pattern of immune activation, and the role of inflammation in the diverse causes of premature Fontan failure and subsequent death.…”

Section: Discussionmentioning

confidence: 99%

Galectin‐3 Is Elevated and Associated With Adverse Outcomes in Patients With Single‐Ventricle Fontan Circulation

Opotowsky

Baraona

Owumi

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundGalectin‐3 may play a role in cardiac and noncardiac fibrosis, and elevated circulating levels of this protein predict adverse outcomes in patients with heart failure who do not have congenital heart disease. We investigated galectin‐3 in adults with single‐ventricle Fontan circulation, patients who are prone to premature clinical deterioration in the context of extensive multiorgan fibrosis.Methods and ResultsWe measured plasma galectin‐3 concentrations in 70 ambulatory adult Fontan patients and 21 age‐ and sex‐matched control participants. Galectin‐3 level was significantly higher in the Fontan group (11.85 ng/mL, interquartile range 9.9 to 15.0 ng/mL) versus the control group (9.4 ng/mL, interquartile range 8.2 to 10.8 ng/mL; P<0.001). Among Fontan patients, galectin‐3 was positively correlated with age, uric acid, and high‐sensitivity C‐reactive protein and negatively correlated with estimated glomerular filtration rate. There was no significant relationship between galectin‐3 and oxygen saturation, Fontan type, or ventricular morphology. Over a median follow‐up of 461 days, 15 events occurred among the Fontan patients: 12 nonelective hospitalizations (with 2 subsequent deaths) and 3 deaths without prior hospitalization. Patients with elevated galectin‐3 (n=19, defined as >2 SD above the control group mean value) had a higher risk of nonelective hospitalization or death (hazard ratio 6.0, 95% CI 2.1 to 16.8, P<0.001). This relationship persisted after individual adjustment for covariates including age, New York Heart Association functional class, C‐reactive protein, and estimated glomerular filtration rate and after multivariable adjustment for independently predictive covariates (hazard ratio 9.2, 95% CI 2.4 to 35.2, P=0.001).ConclusionsGalectin‐3 concentrations are elevated among adults with a Fontan circulation, and elevated galectin‐3 is associated with an increased risk of nonelective cardiovascular hospitalization or death.

show abstract

“…Serum levels of Gal-3 were measured in a cohort of 115 patients affected by CSX demonstrated. They were significantly higher in the CSX patients in comparison with the healthy controls [ 443 ]. This preliminary study needs to be validated in larger number of patients.…”

Section: Xmentioning

confidence: 99%

Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z

Sciacchitano

Lavra

Morgante

et al. 2018

IJMS

286

240

View full text Add to dashboard Cite

Galectin-3 (Gal-3) regulates basic cellular functions such as cell–cell and cell–matrix interactions, growth, proliferation, differentiation, and inflammation. It is not surprising, therefore, that this protein is involved in the pathogenesis of many relevant human diseases, including cancer, fibrosis, chronic inflammation and scarring affecting many different tissues. The papers published in the literature have progressively increased in number during the last decades, testifying the great interest given to this protein by numerous researchers involved in many different clinical contexts. Considering the crucial role exerted by Gal-3 in many different clinical conditions, Gal-3 is emerging as a new diagnostic, prognostic biomarker and as a new promising therapeutic target. The current review aims to extensively examine the studies published so far on the role of Gal-3 in all the clinical conditions and diseases, listed in alphabetical order, where it was analyzed.

show abstract

Serum concentrations of galectin-3 in patients with cardiac syndrome X

Cited by 19 publications

References 29 publications

Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction

Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction

Galectin‐3 Is Elevated and Associated With Adverse Outcomes in Patients With Single‐Ventricle Fontan Circulation

Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z

Contact Info

Product

Resources

About